Evidence map›Paper›PMID 41864344›Full record

ArticleJournal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance

Safety and T

Arutyun Pogosyan, Mary J Keushkerian, Zhengyang Ming, Mostafa Mahmoudi, Myung S Sim, Yuxin Li, J Paul Finn, Kim-Lien Nguyen

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Arutyun PogosyanDivision of Cardiology, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.
Mary J KeushkerianDivision of Cardiology, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.
Zhengyang MingDivision of Cardiology, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System, Los Angeles, California, USA; Physics and Biology in Medicine Graduate Program, University of California, Los Angeles, California, USA; Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Mostafa MahmoudiDivision of Cardiology, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.
Myung S SimDepartment of Medicine Statistics Core, David Geffen School of Medicine at UCLA, California, USA.
Yuxin LiDepartment of Nuclear Medicine, David Geffen School of Medicine at UCLA and VA Greater Healthcare System, Los Angeles, California, USA.
J Paul FinnPhysics and Biology in Medicine Graduate Program, University of California, Los Angeles, California, USA; Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Kim-Lien NguyenDivision of Cardiology, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System, Los Angeles, California, USA; Physics and Biology in Medicine Graduate Program, University of California, Los Angeles, California, USA; Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. Electronic address: klnguyen@ucla.edu.

Funding

Ferumoxytol-Enhanced Cardiac MRI for Ischemic Heart DiseaseR01HL148182 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NGUYEN, KIM-LIEN T · 2020 to 2024
$3.8M
CSRD VA I01 CX001901NHLBI NIH HHS R01 HL148182
6 · The paper itself

Abstract

backgroundFerumoxytol, an intravenous iron supplement that can be used off-label as a contrast agent in cardiovascular magnetic resonance (CMR), has been proposed to enhance the amplitude and dynamic range of myocardial T

methodsSeventy-two participants (ischemic heart disease [IHD]: N = 44, healthy: N = 28) underwent FE-CMR under continuous hemodynamic monitoring. All IHD patients underwent clinically indicated regadenoson stress cardiac positron emission tomography (PET) between 6 days and 31 weeks before FE-CMR. Ferumoxytol was administered in cumulative doses of 3.0 or 4.0 mg/kg, followed by regadenoson. Hemodynamic responses were compared with gadobutrol alone and with regadenoson alone. Post-contrast T

resultsNo severe or life-threatening adverse events occurred. Five patients had mild symptoms. One study was terminated early due to moderate hypotension. Post-ferumoxytol MAP increased slightly (0.1%-3.4%) at rest, without statistical significance. MAP decreased modestly post-regadenoson (-5.3 to -2.8%; all P<0.05). HR remained stable after ferumoxytol administration at rest and increased transiently after regadenoson, consistent with its pharmacologic effect. Unlike the modest MAP increase with ferumoxytol at rest, gadobutrol produced minor MAP decreases (-2.1 to -0.8%), with no significant between-agent differences. FE-T

conclusionsRegadenoson stress FE-CMR is well tolerated. Hemodynamic changes from combined ferumoxytol and regadenoson were small in magnitude and generally not clinically significant. Relative to healthy myocardium, blunted responses were observed in remote, ischemic, and infarcted tissues. Despite early promise, FE-T

Indexed as

Contrast MediaCoronary CirculationFerrosoferric OxideHemodynamicsMagnetic Resonance ImagingMagnetic Resonance Imaging, CineMyocardial IschemiaMyocardial Perfusion ImagingPurinesPyrazolesVasodilator AgentsAdultCase-Control StudiesFemaleHumansMaleContrast MediaFerrosoferric OxidegadobutrolOrganometallic CompoundsPurinesPyrazolesregadenosonVasodilator AgentsCardiac magnetic resonanceContrast mediaFerumoxytolIschemic heart diseaseStress CMRT(1) reactivity

Identifiers

PMID41864344
PMCPMC13241708

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.